ArticlePharmaceuticals (Basel, Switzerland)2022
Combined Administration of (
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- (R)-ketamine induces mGluPsychopharmacology · 2025Article
- Preclinical pharmacokinetic characterization of (R)-ketamine injection, a novel antidepressant glutamatergic agent.Frontiers in pharmacology · 2025Article
- Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation.Pharmacological reports : PR · 2024Article
- Partial mGluPharmacological reports : PR · 2024Article
- TrkB receptor interacts with mGluScience advances · 2024Article
- Ketamine in neuropsychiatric disorders: an update.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications.Frontiers in pharmacology · 2024Review
- mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.European archives of psychiatry and clinical neuroscience · 2023Review
- The antidepressant actions of ketamine and its enantiomers.Pharmacology & therapeutics · 2023Review
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- The Antidepressant-like Activity and Cognitive Enhancing Effects of the Combined Administration of (Pharmaceuticals (Basel, Switzerland) · 2023Article
- Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review.International journal of molecular sciences · 2022Review
- Suppressive Effects of Isofraxidin on Depressive-like Behaviors Induced by Chronic Unpredictable Mild Stress in Mice.Brain sciences · 2022Article
- Hippocampal miR-124 Participates in the Pathogenesis of Depression via Regulating the Expression of BDNF in a Chronic Social Defeat Stress Model of Depression.Current neurovascular research · 2022Article
- Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression.Frontiers in behavioral neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.